Investor Overview

About Nasus

Nasus Pharma is a clinical-stage biopharmaceutical company developing innovative intranasal drug delivery products. Uniquely positioned to address medical emergencies, Nasus Pharma’s Proprietary Nasax® technology is designed to enhance intranasal drug absorption with a potential for longer drug product shelf-life via a unique powder formulation.

NYSE bell ringing interview with Dan Teleman, Nasus CEO

Watch Interview With Dan Teleman

NOTE: A copy of Nasus Pharma Ltd.’s annual report on Form 20-F for the year ended December 31, 2025 has been filed with the U.S. Securities and Exchange Commission at https://www.sec.gov/ and posted on Nasus Pharma Ltd.’s investor relations website at https://ir.nasuspharma.com/. Nasus Pharma Ltd. will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request at IR@nasuspharma.com.
Download Corporate Presentation

Press Releases

March 25, 2026
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
March 16, 2026
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
View All Press Releases

Events

April 16, 2026 12:30 pm ET
Biotech Resurgence: Platforms and Pipelines of Today’s Innovators
March 16, 2026 8:00 am ET
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
View All Events
Scroll to Top
Secret Link